<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fuster, Valentin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The FREEDOM Trial: CABG Superior to PCI in Diabetic Patients with CAD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">In the United States alone, ∼700,000 patients undergo multivessel coronary revascularization yearly. Of these, 25% have diabetes [Smith SC et al. Circulation 2002]. This article presents results from the Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals with Diabetes [FREEDOM] trial.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>